1
|
Vasilakopoulou A, Naas T, Gonzalez C, Vila J, Szabo D, Riccobono E, Kamotsay K, Reissier S, Berbel D, Aszalos AZ, Rosenmoller M, Stankov-Puges M, Georgiou PC, Vourli S, Volland H, Pournaras S. A multicentre evaluation of the NG-test DetecTool OXA-23 for the rapid detection of OXA-23 carbapenemase directly from blood cultures. JAC Antimicrob Resist 2024; 6:dlae029. [PMID: 38455379 PMCID: PMC10919391 DOI: 10.1093/jacamr/dlae029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 02/10/2024] [Indexed: 03/09/2024] Open
Abstract
Objectives A multicentre study evaluating NG-Test DetecTool OXA-23 for the detection of OXA-23 carbapenemase directly from positive blood cultures (PBCs). Methods The NG-Test DetecTool OXA-23 is an immunoassay that integrates a sample preparation device. We evaluated NG-Test DetecTool OXA-23 on 189 spiked and 126 clinical PBCs. The clinical samples' standard-of-care procedure consisted of bacterial identification from the first day of positivity by MALDI-TOF MS, conventional culture and antimicrobial susceptibility testing. The immunoassay results were verified molecularly. The strains used for the spiked samples consisted of well-characterized Acinetobacter baumannii and Proteus mirabilis strains. Results The NG-Test DetecTool OXA-23 was evaluated on 315 PBCs and revealed sensitivity of 100% (95% CI: 98.21%-100.00%) and specificity of 100% (95% CI: 96.73%-100.00%). It provided 204 true-positive results for OXA-23 in 196 bottles with carbapenem-resistant A. baumannii (CRAB) and 8 bottles with carbapenem-resistant P. mirabilis and also provided 111 true-negative results. There were no false-positive and no false-negative results. Among the 315 PBCs studied, 83 clinical blood cultures collected in the ICU of a Greek university hospital, which were tested prospectively, all yielded CRAB, and OXA-23 was correctly detected in all samples from the first day of positivity using the NG-Test DetecTool OXA-23. Conclusions The NG-Test DetecTool OXA-23 has exhibited excellent sensitivity and specificity for OXA-23 detection in PBCs and can provide valuable information for appropriate selection of antibiotic therapy and early implementation of infection control measures.
Collapse
Affiliation(s)
- Alexandra Vasilakopoulou
- Laboratory of Clinical Microbiology, Attikon University General Hospital, Medical School, National and Kapodistrian University, Athens, Greece
| | - Thierry Naas
- Team ‘Resist’, INSERM Unit 1184, Faculty of Medicine, Université Paris-Saclay, Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, AP-HP Paris-Saclay, Bicêtre Hospital Le Kremlin-Bicêtre, Paris, France
| | - Camille Gonzalez
- Team ‘Resist’, INSERM Unit 1184, Faculty of Medicine, Université Paris-Saclay, Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, AP-HP Paris-Saclay, Bicêtre Hospital Le Kremlin-Bicêtre, Paris, France
| | - Jordi Vila
- Department of Clinical Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain
- Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain
- Department of Clinical Microbiology/CIBER de Enfermedades Infecciosas, University of Barcelona, Madrid, Spain
| | - Dóra Szabo
- Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
| | - Eleonora Riccobono
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- Department of Medical Biotechnologies, University of Siena, Siena, Italy
| | - Katalin Kamotsay
- Central Microbiology Laboratory, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary
| | - Sophie Reissier
- Department of Bacteriology, Amiens University Hospital, Amiens, France
| | - Dàmaris Berbel
- Microbiology Department, Hospital de Bellvitge, IDIBELL, UB, CIBERES, Barcelona, Spain
| | - Albert Zoltan Aszalos
- Health Services Management Training Centre, Semmelweis University, Budapest, Hungary
| | - Magda Rosenmoller
- Department of Operations, Information and Technology, IESE Business School, Barcelona, Spain
| | | | - Panagiota-Christina Georgiou
- Laboratory of Clinical Microbiology, Attikon University General Hospital, Medical School, National and Kapodistrian University, Athens, Greece
| | - Sophia Vourli
- Laboratory of Clinical Microbiology, Attikon University General Hospital, Medical School, National and Kapodistrian University, Athens, Greece
| | - Hervé Volland
- Département Médicaments et Technologies Pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI, 91191 Gif-sur-Yvette, Paris, France
| | - Spyros Pournaras
- Laboratory of Clinical Microbiology, Attikon University General Hospital, Medical School, National and Kapodistrian University, Athens, Greece
| |
Collapse
|
2
|
Prado AM, Sánchez-Gómez JI, Casamitjana N, Espriu M, Kumar P, Ngoye B, Bärnighausen T, Rosenmoller M. Building management and innovation capabilities for global health: a senior executive program. Front Public Health 2023; 11:1053745. [PMID: 37705721 PMCID: PMC10497100 DOI: 10.3389/fpubh.2023.1053745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 07/27/2023] [Indexed: 09/15/2023] Open
Abstract
Accurately approaching the major challenges associated with global health management has become a mandatory key point in the training of medical leaders around the world. The Senior Executive Program in Global Health Innovation Management (SEPGHIM) seeks to provide an answer to the need for innovation and managerial capacity building in Global Health and to address the current detachment between Public Health Organizations and Business Schools. In 2019, SEPGHIM's first edition was led by five prestigious academic institutions on three continents. The first cohort included a total of 27 high-level health professionals and executives from 16 countries with 7-10 years of working experience who participated during the 11 months of the course. The program sought to fill an often-found knowledge gap among health professionals in terms of health innovation, leadership, and management. SEPGHIM relied on multiple pedagogical methods conveyed through a robust theoretical and applied syllabus that included case studies, simulations, guest speakers, debates, site visits, and an executive challenge. The program achieved various results. First, it recruited high-level health professionals that ensured diversity of backgrounds, allowing an exchange of experiences and different ways of addressing global health challenges. Second, it created a network of health professionals for possible future collaborations that can anticipate new trends and opportunities in global health and work together with stakeholders from other sectors. This networking was one of the most highly rated benefits by the students. Finally, the participants expressed great eagerness to recommend the program (4.9 out of 5) to other decision-makers and leaders in the global health field. These results provide positive insights regarding the value of such a training program for senior health professionals.
Collapse
Affiliation(s)
- Andrea M. Prado
- Management and Organizations Department, INCAE Business School, Alajuela, Costa Rica
| | | | - Núria Casamitjana
- Instituto de Investigación de la Universidad de Barcelona, Instituto Salud Global Barcelona (ISGlobal), Barcelona, Spain
- Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
| | - Marina Espriu
- Instituto de Investigación de la Universidad de Barcelona, Instituto Salud Global Barcelona (ISGlobal), Barcelona, Spain
| | - Pratap Kumar
- Strathmore Business School, Strathmore University, Nairobi, Kenya
| | - Ben Ngoye
- Strathmore Business School, Strathmore University, Nairobi, Kenya
| | - Till Bärnighausen
- Heidelberg Institute of Global Health, Heidelberg University Hospital, Heidelberg, Baden-Württemberg, Germany
| | | |
Collapse
|
3
|
Volland H, Ballesté-Delpierre C, Szabó D, Gonzalez C, Takissian J, Aszalos AZ, Ostorhazi E, Farkas S, Kamotsay K, Rosenmoller M, Stankov-Pugès M, Francius L, Boutigny L, Sivan V, Simon S, Gelhaye S, Bosch J, Vila J, Naas T. Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool. J Antimicrob Chemother 2022; 77:2867-2875. [PMID: 35978470 DOI: 10.1093/jac/dkac264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 07/15/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Lateral flow immunoassays (LFIA) have shown their usefulness for detecting CTX-M- and carbapenemase-producing Enterobacterales (CPEs) in bacterial cultures. Here, we have developed and validated the BL-DetecTool to detect CTX-M enzymes and carbapenemases directly from clinical samples. METHODS The BL-DetecTool is an LFIA that integrates an easy sample preparation device named SPID (Sampling, Processing, Incubation and Detection). It was evaluated in three University hospitals on urine, blood culture (BC) and rectal swab (RS) specimens either of clinical origin or on spiked samples. RS evaluation was done directly and after a 24 h enrichment step. RESULTS The CTX-M BL-DetecTool was tested on 485 samples (154 BC, 150 urines, and 181 RS) and revealed a sensitivity and specificity of 97.04% (95% CI 92.59%-99.19%) and 99.43% (95% CI 97.95%-99.93%), respectively. Similarly, the Carba5 BL-DetecTool was tested on 382 samples (145 BC, 116 urines, and 121 RS) and revealed a sensitivity and specificity of 95.3% (95% CI 89.43%-98.47%) and 100% (95% CI 98.67%-100%), respectively. While with the Carba5 BL-DetecTool five false negatives were observed, mostly in RS samples, with the CTX-M BL-DetecTool, in addition to four false-negatives, two false-positives were also observed. Direct testing of RS samples revealed a sensitivity of 78% and 86% for CTX-M and carbapenemase detection, respectively. CONCLUSIONS BL-DetecTool showed excellent biological performance, was easy-to-use, rapid, and could be implemented in any microbiology laboratory around the world, without additional equipment, no need for electricity, nor trained personnel. It offers an attractive alternative to costly molecular methods.
Collapse
Affiliation(s)
- Hervé Volland
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Clara Ballesté-Delpierre
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain
| | - Dóra Szabó
- Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary
| | - Camille Gonzalez
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France
| | - Julie Takissian
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France
| | - Albert Zoltan Aszalos
- Semmelweis University, Health Services Management Training Centre, Budapest, Hungary
| | - Eszter Ostorhazi
- Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary
| | - Szilvia Farkas
- Semmelweis University, Health Services Management Training Centre, Budapest, Hungary
| | - Katalin Kamotsay
- Central Microbiology Laboratory, Central Hospital of Southern Pest National Institute of Hematology and Infectious Disease, Budapest, Hungary
| | | | | | | | | | - Virginie Sivan
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Stéphanie Simon
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Stéphanie Gelhaye
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Jordi Bosch
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain.,University of Barcelona, Hospital Clínic, Department of Clinical Microbiology - CDB, Barcelona, Spain
| | - Jordi Vila
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain.,University of Barcelona, Hospital Clínic, Department of Clinical Microbiology - CDB, Barcelona, Spain.,CIBER de Enfermedades Infecciosas (CIBERINFEC), ISCIII, Madrid, Spain
| | - Thierry Naas
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France.,Team 'Resist' UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB)', INSERM, University Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.,Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-producing Enterobacterales, Le Kremlin-Bicêtre, France
| |
Collapse
|